Aspirin placebo

Preclinical

BBeijing Tiantan Hospital

Aspirin placebo is one of 5 therapeutic programs targeting Moyamoya disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Moyamoya DiseaseNot yet recruiting

Moyamoya DiseasePreclinical

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Moyamoya Disease

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Preclinical

1 2

Sufenta

LLeaf Vertical Inc.

Preclinical

1 3

Aspirin Treatment

VVA Office of Research and Development

Preclinical

1 4

Aspirin placebo

BBeijing Tiantan Hospital

Preclinical

1 5

Revascularization/conservative Management

MMinia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

PreclinicalNot yet recruiting

Moyamoya Disease

NCT07762547

Clinical

Trials by Indication[1]

Moyamoya disease1 trial

Study on the Effects of Pharmacological and Physical Therapy in Delaying the Progression of Moyamoya Disease (Moyamoya Syndrome) : Randomized Controlled Study

Not yet recruiting·BBeijing Tiantan Hospital·Preclinical·NCT07762547·724 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Aspirin placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Aspirin placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Beijing Tiantan Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: BBeijing Tiantan Hospital

Aspirin placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Moyamoya disease1 trial

References

Drug Info

Quick Facts

Related News